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We describe a case of severe leukocytosis caused by leukemic mantle cell lymphoma 
(MCL), complicated by leukostasis with myocardial infarction in which leukapheresis was 
used  in  the  initial  management.  A  73-year-old  male  presented  to  the  emergency 
department because of fatigue and thoracic pain. Blood count revealed 630  10
9/L WBC 
(white  blood  cells).  The  electrocardiogram  showed  ST-elevation  with  an  increase  of 
troponin  and  creatinine  kinase.  The  diagnosis was  ST-elevation  myocardial  infarction 
(STEMI)  induced  and  complicated  by  leukostasis.  Immunophenotyping,  morphology, 
cytogenetic and fluorescence-in-situ-hybridization analysis revealed the diagnosis of a 
blastoid variant of MCL. To remove leukocytes rapidly, leukapheresis was performed in 
the intensive care unit. Based on the differential blood count with 95% blasts, which were 
assigned  to  the  lymphocyte  population  by  the  automatic  hematology  analyzer, 
leukapheresis  procedures  were  then  performed  with  the  mononuclear  cell  standard 
program on the Spectra cell separator. The patient was treated with daily leukapheresis 
for 3 days. The WBC count decreased to 174  10
9/L after the third leukapheresis, with a 
72%  reduction.  After  the  second  apheresis,  treatment  with  vincristine, 
cyclophosphamide,  and  prednisolone  was  started.  The  patient  fully  recovered  in  the 
further course of the treatment. To the best of our knowledge, this is the first report on 
blastoid MCL with leukostasis associated with a STEMI that was successfully treated by 
leukapheresis. Effective harvest of circulating lymphoma cells by leukapheresis requires 
adaptation of instrument settings based on the results of the differential blood count 
prior to apheresis. 
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INTRODUCTION 
Rapid reduction in the number of circulating blast cells is essential when treating patients with acute 
hyperleukocytosis (white blood cell [WBC] counts >100,000/mm
3). Many early complications and death 
can  be  directly  attributed  to  hyperleukocytosis  and  its  resultant  microcirculatory  dysfunction,  a 
phenomenon referred to as leukostasis[1,2,3]. Leukapheresis has been widely used in the treatment of 
acute hyperleukocytosis because of its immediate cytoreductive effect[3,4,5,6]. However, patients with 
lymphoid malignancies rarely develop leukostasis, but may undergo cytoreduction with leukapheresis as 
prophylaxis for tumor lysis[6,7]. Here, we report a case of severe leukocytosis caused by a mantle cell 
lymphoma (MCL), a blastoid variant, complicated by leukostasis in which leukapheresis was used in the 
initial  management.  A  blastoid  variant  of  MLC  is  a  morphologic  variant  characterized  by  large, 
noncleaved cells with fine chromatin and inconspicuous nucleoli. Reports of MCL with blastoid variant, 
defined as seen in the current case, are rare[8,9,10,11]. Until now, only one prior report described a 
blastoid MCL with a leukocyte count of 405   10
9/L[10]. To the best of our knowledge,  our study 
represents the first reported case of a leukemic MCL, blastoid variant, with a hyperleukocytosis of 630  
10
9/L, complicated with leukostasis causing a myocardial infarction (MI). Leukapheresis was successfully 
performed  for  a  rapid  reduction  of  circulating  lymphoma  cells,  resulting  in  an  improvement  of  the 
patient’s condition. 
CASE REPORT AND RESULTS 
A 73-year-old male presented to the emergency department because of fatigue and chest pain. He had no 
fever, chills, or night sweats. He had a history of peripheral artery occlusive disease and coronary heart 
disease, with coronary angioplasty and stent implantation in 1998. On physical examination, he appeared 
fatigued and had a mild dyspnea. The blood pressure, pulse, and oxygen saturation were at 160/85 mm, 
90  beats  per  minute,  and  95%,  respectively.  His  lungs  were  clear  to  auscultation.  He  had  no 
splenomegaly,  adenopathy,  hepatomegaly,  or  skin  lesions.  Differential  blood  count  and  morphology 
revealed  an  extreme  leukocytosis  of  600    10
9/L  WBC,  with  95%  lymphoma  cells  assigned  as 
mononuclear cells (MNC)(Fig. 1). Hematocrit (Hct) and platelet count were at 27% and 108  10
9/L, 
respectively. Laboratory investigations revealed elevated values of - GT, ASAT, AP, LDH, uric acid, 
CRP, and fibrinogen with 93 U/L (0-55), 96 U/L (0-37), 341 U/L (38-126), 795 U/L (0-248), 10.4 mg/dL 
(2.5-5.7),  92  mg/L  (0-5),  and  6.01  g/L  (1.5-4.5),  respectively.  Measurements  of  the  electrolytes, 
coagulation indices (PTT,  INR),  creatinine,  cardiac  enzymes  CPK,  and  troponin-I  were  normal.  The 
patient was admitted to the intensive care unit for further treatment. Based on the electrocardiogram and 
the cardiac enzymes at the time of admission to the intensive care unit, MI could be excluded. To remove 
leukocytes rapidly, therapeutic leukapheresis was immediately induced after the admission of the patient 
to the intensive care unit.  In order to choose the appropriate collection program on the Spectra cell 
separator for the effective harvest of circulating lymphoma cells, a differential blood count was performed 
before apheresis using an automatic hematology analyzer and revealed a further increase of WBC with 
630  109/L differentiated in neutrophils 1%, lymphocytes 88%, monocytes 8%, and eosinophils 3%. Due 
to  the  fact  that  lymphoma  cells  were  assigned  to  the  lymphocyte  and  monocyte  population  by  the 
hematology analyzer, leukapheresis procedures were then performed with the MNC standard program on 
the cell separator. The total volume of leukocyte-rich plasma removed ranged from 513–600 mL per 
treatment.  Each  apheresis  required  2–3  h to  complete.  After the first  leukapheresis, the WBC  count 
decreased to 409  10
9/L. Prior to the second apheresis, the WBC count increased to 541  10
9/L. At that 
time, the patient reported dyspnea. The electrocardiogram showed a ST-elevation in the ECG channels 
V1–V4 and a negative T wave in channels I, II, and aVF. The values of troponin-I and CPK increased to 
0.8 µg/L (0-0.5) and 207 U/L (0-145), respectively. Thus, the diagnosis was ST-elevation myocardial 
infarction (STEMI) induced and complicated by leukostasis. Because of the reduced physical status of the  Nguyen et al.: Therapeutic Apheresis in Leukemic Mantle Cell Lymphoma  TheScientificWorldJOURNAL (2011) 11, 1554–1559 
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FIGURE  1.  Peripheral  blood  smear.  A  population  of  mantle  cells  with  cleaved 
nucleus  and  paucity  of  cytoplasma  (May-Grünwald-Giemsa  staining,  original 
magnification 1160). The majority of cells in the figure appear cleaved, showing an 
unusual variant of MCL. 
patient, an angioplasty could not be performed. Due to the STEMI, the following apheresis procedures 
were performed without transfusion of platelets (PLT), while the patient’s PLT decreased to 60  10
9/L 
and 35  10
9/L prior to the second and third apheresis, respectively (Fig. 2). The patient was treated with 
daily leukapheresis for 3 days. The WBC count decreased to 174  10
9/L after the third leukapheresis, 
with an elimination rate of 43% reduction (35–49%) in WBC count per leukapheresis (Fig. 2). The patient 
showed a relief of symptoms after the second apheresis, with a decrease of WBC count from 541  10
9/L 
to  305    10
9/L.  The  CPK  and  troponin-I  went  back  to  143  U/L  (0-145)  and  0.68  µg/L  (0–0.5), 
respectively. After 1 week, troponin-I and ECG had fully recovered.  
According  to  the  immunophenotyping  by  flow  cytometry  (3-color  machine,  Becton  Dickinson, 
Heidelberg, Germany), the lymphoma cells were positive for CD5, CD19, CD20, CD22, CD24, CD25, 
CD38, CD79, FMC7, and HLA-DR. The cells were monoclonal for lambda with a strong expression of 
the light chain. The investigation on CD1, CD2, CD3, CD4, CD8, CD10, CD11c, CD13, CD14, CD15, 
CD16, CD23, CD34, CD56, CD61, CD65, CD103, CD117, CD235, myeloperoxidase, and TdT showed a 
negative result. Fluorescence-in-situ-hybridization (FISH) was performed using the IGH-CCND1 (t11;14) 
probe  (ABBOTT).In  93  of  100  analyzed  peripheral  blood  interphase  cells,  the  typical  colocalization 
signal for the IGH-CCND1 rearrangement confirming translocation (11;14) was detected. 
All the results were consistent with MCL, blastoid variant. Treatment with vincristine (1 mg once), 
cyclophosphamide (350 mg/die for 5 days), and prednisolone (100 mg/die) was started after the second 
leukapheresis. The WBC count dropped to 11  10
9/L after 2 weeks. The patient recovered fully and 
induction chemotherapy was scheduled in the outpatient clinic. Unfortunately, the patient declined further 
treatments and missed follow-up appointments. Nguyen et al.: Therapeutic Apheresis in Leukemic Mantle Cell Lymphoma  TheScientificWorldJOURNAL (2011) 11, 1554–1559 
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FIGURE 2. WBC count and PLT over time. The patient underwent three sessions of 
leukapheresis. Chemotherapy with vincristine, cyclophosphamide, and prednisolone was 
started after the second apheresis.  
MATERIALS AND METHODS 
All leukapheresis procedures were performed with the Spectra cell separator (Cobe BCT, Lakewood, CO, 
USA)  by  using  the  V5.1  software  and  the  MNC  standard  program.  The  cell  separator  was  set  in 
accordance  with  the  manufacturer’s  recommendation.  Peripheral  venous  access  was  performed  with 
cubital venipuncture. ACD-A was used as anticoagulant with an ACD-A blood ratio of 1:15. Whole-
blood inlet flow rates of 50 mL/min were adjusted by the system according to size of the patient (sex, 
height, and weight) to reduce the risk of citrate reactions. No adverse reactions during the collections 
were observed. The collection flow rate was 6 mL/min, and the plasma pump rate was visually adapted to 
target a product’s Hct of around 2% by using the color index provided with this apheresis device. No 
sedimenting agents were added to the blood. 
DISCUSSION 
Leukemic MLC shows a very aggressive clinical course and is associated with poor prognosis; survival 
ranges between 1.5 and 37 months[8,10]. Particularly, blastoid MCL subtypes were characterized by 
distinctly  elevated  mitotic  counts  and  proliferation  indices[12].  Hyperleukocytosis  may  result  in 
leukostasis  syndrome  characterized  by  impaired  flow  and  accumulation  of  leukemic  cells  in  the 
microvasculature. Leukostasis can affect any organ system. Symptoms usually arise from involvement of 
the pulmonary and cerebral microvasculature, and most early deaths are due to respiratory failure and 
intracranial  hemorrhage[13,14].  Leukapheresis  has  been  used  for  rapid  treatment  of  acute 
hyperleukocytosis. Although there are no widely accepted protocols for when to start leukapheresis, it is 
usually  initiated  in  any  patients  with  AML  with  a  blast  count  >100,000/mm
3  or  in  the  presence  of Nguyen et al.: Therapeutic Apheresis in Leukemic Mantle Cell Lymphoma  TheScientificWorldJOURNAL (2011) 11, 1554–1559 
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symptoms  of  leukostasis,  irrespective  of  the  blast  count[4,14].  However,  leukapheresis  is  rarely 
performed in ALL or leukemic transformation of lymphomas unless symptoms of leukostasis or blast 
counts >300,000/mm
3 are seen[14].  
Here, we report a case of MCL, blastoid variant, with an extreme leukocytosis complicated with a 
leukostasis associated with STEMI. The diagnosis was confirmed by morphology, immunophenotyping, 
cytogenetic  and  FISH  analysis.  Only  a  few  cases  of  AML  coincident  with  acute  MI  were 
reported[15,16,17,18] and only one of these reports described cardiac manifestations of leukostasis[15]. 
Until chemotherapy effectively reduces circulating lymphoma cells, high-volume leukapheresis can be 
temporarily performed to manage peripheral leukocytosis. Daily treatments may be necessary until the 
production  of  WBC  can  be  controlled.  Porcu  et  al.  identified  older  age,  respiratory  or  neurological 
symptoms,  coagulopathy,  and  renal  failure  as  risk  factors  for  early  death  in  patients  with 
hyperleukocytosis in acute leukemia. This subgroup of patients benefits from prompt and significant 
leukoreductions[4]. Additionally, the physical removal of a large number of leukemic cells and the ability 
to administer fresh plasma and electrolytes during a single procedure may significantly reduce the risk of 
hemorrhage and tumor lysis syndrome[19].  
To the best of our knowledge, this is the first report on blastoid MCL with leukostasis associated with 
a  STEMI  that  was  successfully  treated  by  leukapheresis.  In  order  to  improve  the  WBC  harvest,  we 
routinely perform a differential blood count before apheresis. The MNC or PMN (polymorphonuclear) 
standard program was accordingly chosen for the leukapheresis procedure on the cell separator. Due to 
assignment of the circulating lymphoma cells to the lymphocyte population (mononuclear cell population) 
by  the  automatic  hematology  analyzer,  the  MNC  standard  program  was  selected.  Therefore,  an 
erythrocyte  sedimentation  agent  such  as  hydroxyethyl  starch  for  returning  red  cells  for  a  better 
elimination of polymorph cells like granulocytes was not necessary. With the past history of coronary 
heart disease, the patient was at high risk for MI during leukostasis. A STEMI developed 1 day after 
admission to the intensive care unit. After the second apheresis with a decrease of the WBC count, the 
patient showed a complete relief of symptoms correlating with a decrease of CPK and troponin-I. Despite 
the thrombocytopenia in the patient and the fact of PLT loss due to apheresis[20], transfusion of PLT was 
not applied, in order to avoid a possible enhancement of clotting that may have aggravated the STEMI. 
The coagulation indices were normal at the time of apheresis. Nonetheless, peripheral blood PLT levels 
above  30    10
9/L  before  collection  are  sufficient  for  a  safe  leukapheresis[21].  The  reported  case 
demonstrates  effective  removal  of  circulating  lymphoma  cells  through  leukapheresis,  with  a  72% 
reduction  in  WBC  count.  Due  to  cytoreduction  by  chemotherapy,  three  leukapheresis  sessions  were 
sufficient.  
In conclusion, leukapheresis is an effective and rapid treatment of leukocytosis complicated with 
leukostasis.  It  is  possible  that  progression  of  the  leukostasis-associated  STEMI  was  interfered  with 
through  continued  leukapheresis.  Effective  harvest  of  circulating  lymphoma  cells  by  leukapheresis 
requires adaptation of instrument settings based on the results of the differential blood count prior to 
apheresis.  
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